| Autor: |
zeyqami, Ali, Babaei, Arvin, Ghorbannezhad, Mobina, Nematizadeh, Mona, Kochakzadeh, Zahra, Dahri, Monireh |
| Předmět: |
|
| Zdroj: |
Journal of Nutrition, Fasting & Health; 2022 Supplement, Vol. 10, p180-181, 2p |
| Abstrakt: |
Purpose of review: Selenium (Se) is recognized for its antioxidant vital role in neurodegenerative disorders, including Alzheimer's disease (AD). Lower concentrations of Se have been seen in the patients with AD. In this review, we discussed the role of Se in AD. Recent findings: In the most studies it has been demonstrated serum Se levels were decreased in AD patients compare with healthy controls. Also, they had reduced antioxidant levels e.g., it was shown a significant decrease in total antioxidant capacity (TAC) and glutathione (GSH). In reverse in some studies is shown inflammatory factors such as Tumor necrosis factor-α (TNF-α) and high sensitivity C-reactive protein (hs-CRP) has increased. So due to Se antioxidant function it can have neuroprotective role in AD. In interventional studies it is shown Se supplementation, with or without other antioxidants such as vitamin E and resveratrol, can lead to reduced levels of inflammatory factors and oxidative stress. It also has improving results on cognitive performance, which is assessed by MMSE (mini-mental status examine). In addition, Amyloid-ß, which triggers neurodegenerative processes, increased due to high levels of oxidative stress in AD patients and Se has protective regulatory role in the production of Amyloid-ß. Conclusion: Recent studies have shown that serum Selenium can have protective effects on increasing inflammatory factors, Amyloid-ß and oxidative stress which reduce the symptoms in AD patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
